ANTI-CD19 COMBINATION THERAPY
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antib...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
11.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antibody, lenalidomide, and rituximab for use in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia. |
---|---|
Bibliography: | Application Number: EP20210819888 |